In context of Non Small Cancer Lung Cells (NSCLC), it was shown that clinical responses were linked to activating mutations within EGFR tyrosine kinase domain, suggesting that better understanding of biological effects of EGFR inhibitors on cancer will help identify tumors that will respond to therapy [3], [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.